Eli Lilly and NVIDIA both reported strong quarterly results, with Lilly growing 47.7% driven by obesity drugs Mounjaro and Zepbound, and NVIDIA soaring 105.8% on AI data center demand. Lilly focuses on expanding its pharmaceutical portfolio and manufacturing capacity, while NVIDIA leads in AI infrastructure with massive third-party capital backing. Analysts favor NVIDIA for its rapid revenue growth and platform strategy despite some margin risks, while Lilly offers defensive exposure with dividend growth. The choice for a $10,000 investment in 2026 depends on whether investors prioritize high growth in AI or steady gains in healthcare innovation.
Eli Lilly's biggest shareholder, the Lilly Endowment, filed to sell 300,000 shares worth $347 million, driven by a legal payout requirement rather than company performance concerns. Despite the sale, analysts continue to raise price targets, with Mor...
Cantor Fitzgerald increased price targets for four major pharmaceutical companies: Eli Lilly, AbbVie, Merck, and Pfizer, while maintaining their current ratings. Eli Lilly and AbbVie received Overweight ratings with higher targets, reflecting stronge...
Eli Lilly's Phase 3b TOGETHER-PsO trial revealed that combining Taltz (ixekizumab) and Zepbound (tirzepatide) led to broader changes in psoriasis and metabolic biomarkers compared to Taltz alone as early as Week 12. This suggests a linked immune-meta...
At the Veeva R&D and Quality Summit in Boston, leading biopharma companies like Eli Lilly, Pfizer, and Sanofi shared innovations in AI, cloud platforms, and connected trials to accelerate drug development and improve quality. Highlights include Eli L...
Novo Nordisk is rated as a Buy compared to Eli Lilly because it trades at a significant valuation discount of about 26% to its big pharma peers despite having similar growth rates and a strong dividend yield. The stock is priced at roughly 11.2 times...
